First nasal Covid-19 vaccine iNCOVACC by Bharat Biotech okayed for heterologous booster doses
New Delhi, November 28: Bharat Biotech's iNCOVACC intranasal vaccine against Covid 19 has received CDSCO approval under restricted use in emergency for heterologous booster doses for ages 18 and above.
Notably, Bharat Biotech, Hyderabad-based biotechnology company, has launched the world's first nasal Covid-19 vaccine — iNCOVACC.
According to a tweet shared by Bharat Biotech on Monday evening, iNCOVACC recently received approval under Restricted Use in Emergency Situation for ages 18 and above for heterologous booster doses.
Also Read| Punjab ministers, MLAs on field visit can now stay at circuit, govt guest houses only
In heterologous booting doses, a person is administered a different vaccine from the one that used for the primary dose.
iNCOVACC has become world's first intranasal vaccine for Covid-19 to receive approval for heterologous booster dose, according to the statement.
Also Read | Australia's most promising cricketer Cameron Green confirms registration for IPL 2023 auctions
Earlier, the nasal vaccine had received approval under Restricted Use in Emergency Situation for ages 18 and above for the primary 2-dose schedule. Phase III trials were conducted for safety, immunogenicity in 3,100 subjects at 14 sites across the country.
iNCOVACC, World's first intranasal vaccine to receive both primary series and Heterologous booster approval. #bharatbiotech #incovacc #intranasalvaccine #vaccine #COVID19 #VaccinesWork #VaccineDevelopment #Booster #COVID #pandemic #firstintranasalvaccine pic.twitter.com/jyTebvwiT6 — BharatBiotech (@BharatBiotech) November 28, 2022
- PTC NEWS
